Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dose of nab-paclitaxel to be safely
administered in combination with pembrolizumab in patients with advanced inoperable non-small
cell lung cancer. The study is also aimed at evaluating the efficacy of the combination
therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators:
Celgene Celgene Inc Centre de Recherche du Centre Hospitalier de l'Université de Montréal Jewish General Hospital Merck Canada Inc Merck Canada Inc.